Charles Piller, author of 'Doctored,' exposes the dark realities in Alzheimer's research, revealing how esteemed scientists faced allegations of data manipulation. He shares the rise and fall of the controversial drug simufilum, initially thought to reverse memory loss. Piller discusses the historical amyloid hypothesis and its limitations, alongside the challenges of scientific integrity and groupthink in the field. Lastly, he emphasizes the need for renewed trust in scientific institutions amidst growing concerns over fraud and stagnation in effective treatments.

In this discussion, Charles Piller, an investigative journalist for Science Magazine and author of "Doctored," dives deep into corruption in Alzheimer's research. He reveals shocking details about unethical practices, data manipulation, and the immense pressures faced by researchers. The conversation also touches on the failures of the FDA, the implications of the amyloid hypothesis, and the dire need for accountability in science. Piller advocates for restoring trust and transparency in medical research to foster better patient outcomes.

Charles Piller, an investigative journalist for Science Magazine and author of "Doctored," exposes the dark side of Alzheimer's research. He reveals how fraudulent studies, like one that cemented the amyloid hypothesis, misled the field for decades. Piller discusses NIH funding incentives encouraging flawed research and the heroic roles of whistleblowers uncovering manipulation. He underscores the urgent need for transparency while highlighting promising new avenues in treatment, such as viral research and GLP-1 inhibitors, instilling hope for patients and families alike.

Charles Piller, an investigative journalist at Science Magazine and author of "Doctored," delves into the murky waters of Alzheimer’s research. He discusses alarming allegations of scientific fraud, including manipulated images that undermine research integrity. Piller explores the controversies surrounding the Alzheimer's drug semifilam, revealing the FDA's complicity in oversight failures. The conversation highlights the importance of ethics and accountability in science, emphasizing how fraudulent practices can derail crucial advancements in treatment.

Charles Piller, an award-winning investigative correspondent for Science Magazine and nine-time Pulitzer Prize nominee, dives into the troubling manipulation of Alzheimer's research. He discusses the dangers of fraudulent studies and highlights the case of the drug Simufilum. Piller examines how misinformation has skewed research funding and emphasizes the importance of lifestyle choices in reducing Alzheimer’s risk. He also critiques the financial ties between advocacy groups and pharma, advocating for transparency and integrity in scientific research.